DealsJul 21, 2026, 07:14 AM
Jupiter Neurosciences Licenses ALA-002 for up to $100M
AI Summary
Jupiter Neurosciences, Inc. announced a definitive license agreement with PharmAla Biotech Holdings Inc. for perpetual exclusive U.S. rights to ALA-002, a patented, non-racemic MDMA formulation with FDA Novel Chemical Entity designation. The deal is valued at up to $100 million, including milestone payments, and includes an upfront payment of $3.3 million. This transaction significantly expands Jupiter's pipeline, transforming it into a dual clinical-stage CNS company alongside its Parkinson's disease program, and leverages a favorable regulatory environment for psychedelic therapies.
Key Highlights
- Secured perpetual exclusive U.S. rights to ALA-002 from PharmAla Biotech Holdings Inc.
- Transaction has a potential value of up to $100M, including milestone payments.
- Upfront payment of $3.3M ($1.5M cash + $1.8M JUNS common stock).
- Includes a $3.3M development milestone upon Phase 3 First Patient In.
- Regulatory milestone of $20M upon U.S. NDA Approval.
- Commercial milestones total $73.3M at $333M, $1B, and $2B cumulative U.S. net sales.
- ALA-002 is an FDA NCE-designated, non-racemic MDMA formulation with enhanced regulatory protection.
- Expands Jupiter into a dual clinical-stage CNS company, adding a second program.
Price Impact
More from JUNS